Plain-English translation of NCT04513028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a natural supplement called beta-glucan can enhance how well pembrolizumab works to fight melanoma. Pembrolizumab is an immunotherapy medication that helps your immune system recognize and attack cancer cells. The study will look at whether adding the supplement improves immune markers in your blood and helps prevent the cancer from coming back.
Even with effective immunotherapy like pembrolizumab, some people with advanced melanoma experience cancer recurrence. Researchers want to know if this supplement might strengthen the body's immune response to make the immunotherapy work even better and reduce the risk of the cancer returning.
You likely qualify if…
You likely don't qualify if…
You will receive your regular pembrolizumab infusions every three weeks as you normally would. In addition, you will take beta-glucan capsules by mouth twice daily for 21 days. The study lasts about 6 weeks total, and researchers will draw blood samples to check immune markers and monitor how well this combination works. You may also be followed longer to track whether your cancer stays away.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Sponsor
Kelly McMasters
Enrollment target
~30 participants
Started
November 2020
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Matthew Woeste, MD
University of Louisville
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.